Phase II Biomarker Study of SAR444881 in Combination With Cemiplimab in Solid Tumors
Latest Information Update: 24 Oct 2024
At a glance
- Drugs BND 22 (Primary) ; Cemiplimab
- Indications Colorectal cancer; Non-small cell lung cancer; Ovarian cancer; Solid tumours
- Focus Adverse reactions; Biomarker
- 24 Oct 2024 New trial record